clinical trial · NCT05907668
A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' Disease
Immunovant Sciences GmbH·phase2·completed·n = 35
Graves DiseaseIMVT-1401 (batoclimab)
brief summary
The purpose of this study is to assess the efficacy and safety of 24 weeks of treatment with batoclimab in adult participants with biochemically documented hyperthyroidism due to GD who have failed to achieve euthyroidism on antithyroid drugs (ATDs).
started
May 15, 2023
primary completion
Jul 25, 2025
completion
Jul 25, 2025
last updated
Feb 2, 2026
official title
IMVT-1401-2501: A Proof-of-Concept, Open-label Study to Assess the Safety and Efficacy of Batoclimab in Participants With Graves' Disease (GD)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol